Abstract Background Glioblastoma (GBM), the most prevalent and aggressive primary brain tumor in adults, has a median survival of merely 14 months. Current therapeutic approaches, including maximal safe resection, radiotherapy, and temozolomide-based chemotherapy, have limited efficacy owing to resistance and the high rate of recurrence. Methods We analyzed H this strategy repurposes venetoclax, a known clinical drug for leukemia, as a PTBP1-targeting agent that effectively suppresses glioma progression in mouse models. Conclusion Our findings establish a novel PTBP1/DUSP5/ERK1/2 axis governing glioma stem cell proliferation and differentiation and identify the A2-PLGA/venetoclax nanoparticle as a mechanistically justified therapeutic candidate for glioblastoma.
Li et al. (Tue,) studied this question.